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Adjuvants constitute an important class of products for the development of modern vaccines, especially for 
vaccines based on highly purified protein antigens. However, there are only a few adjuvants that are used in 
licensed human vaccines, with aluminum salts (AlOOH and AlPO4) and squalene emulsions (AS03, MF59) 
being the most widely injected adjuvants in humans.  
 
While simple aluminum salts and emulsion adjuvants are very good at increasing antibody and Th-2 responses, 
they often lack the ability to induce strong Th-1 type cellular responses. One approach to increase the capacity 
of these adjuvants to induce Th-1 responses is to combine them with a small molecular weight 
immunopotentiator, such as a Toll-like receptor (TLR) agonist. We and others found that formulation plays an 
important role when developing such adjuvant combinations. With the example of a small molecule TLR-4 
agonist, E6020, combined respectively to aluminum salt and to a squalene emulsion, this presentation will 
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